Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC lowered its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 0.2% in the third quarter, HoldingsChannel reports. The firm owned 1,086,899 shares of the company’s stock after selling 2,405 shares during the period. Geode Capital Management LLC’s holdings in Pacira BioSciences were worth $16,361,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of PCRX. Pacer Advisors Inc. increased its stake in Pacira BioSciences by 129.4% during the third quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock worth $74,681,000 after acquiring an additional 2,799,434 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Pacira BioSciences by 9.8% in the 2nd quarter. Renaissance Technologies LLC now owns 2,066,197 shares of the company’s stock valued at $59,114,000 after acquiring an additional 184,000 shares during the period. State Street Corp raised its stake in shares of Pacira BioSciences by 5.8% in the 3rd quarter. State Street Corp now owns 2,014,012 shares of the company’s stock valued at $30,311,000 after acquiring an additional 110,162 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Pacira BioSciences by 12.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company’s stock worth $52,300,000 after purchasing an additional 198,936 shares during the period. Finally, Doma Perpetual Capital Management LLC lifted its stake in Pacira BioSciences by 71.8% during the second quarter. Doma Perpetual Capital Management LLC now owns 1,000,761 shares of the company’s stock worth $28,632,000 after purchasing an additional 418,321 shares in the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Barclays lowered their target price on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a report on Tuesday, November 12th. Jefferies Financial Group upped their price objective on Pacira BioSciences from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. HC Wainwright reiterated a “buy” rating and issued a $39.00 target price on shares of Pacira BioSciences in a report on Wednesday, December 4th. Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Pacira BioSciences in a research note on Friday, November 8th. Finally, Royal Bank of Canada raised their target price on Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $23.50.

Pacira BioSciences Stock Down 0.8 %

PCRX stock opened at $19.65 on Monday. The stock has a market capitalization of $907.30 million, a PE ratio of -9.68 and a beta of 0.80. The company has a fifty day moving average of $17.91 and a 200-day moving average of $18.25. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $35.95.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.